申请人:Bristol-Myers Squibb Company
公开号:EP2280012A2
公开(公告)日:2011-02-02
The present invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
本发明提供了式(I)化合物及其药学上可接受的盐类。式(I)化合物可抑制生长因子受体(如 VEGFR-2 和 FGFR-1)的酪氨酸激酶活性,因此可用作抗癌剂。式 (I) 化合物还可用于治疗与通过生长因子受体运行的信号转导通路有关的其他疾病。